Expression of MT-3 gene in esophageal squamous cell carcinoma and its relationship with patient's prognosis

doi:10.3969/j.issn.1002-7386.2017.12.001

Abstract：Objective To investigate the expression of MT-3 gene in esophageal squamous cell carcinoma and its relationship with postoperative pathology and patient's prognosis.Methods A retrospective study was performed in 96 patients with esophageal squamous cell carcinoma who received surgical resection in our hospital from 2009 to 2011.Immunohistochemical staining was used to detect the expression of MT-3 gene in tumor tissues.The χ2 test was used to evaluate the correlation, and Kaplan-meier method was used to analyze survival rate,moreover,Log-rank test was used to determine survival difference.The Cox regression analysis was performed to determine the independent prognostic risk factors.Results Among 96 specimens,there were 41 cases of positive expression of MT-3 gene,accounting for 41.28%.The negative expression of MT-3 in esophageal squamous cell carcinoma was closely correlated with tumor differentiation,T staging and lymph node metastasis (P<0.05 or P<0.01).Among 96 patients,the 3-year survival rate accounted for 45.9%,in which the patients with negative expression of MT-3 gene accounted for 20.1%,and the patients with positive expression of MT-3 gene accounted for 52.6%,there was a significant difference between them (P<0.05).Cox regression analysis showed that tumor differentiation degree,lymph node metastasis and negative expression of MT-3 gene were prognostic risk factors in patients with esophageal carcinoma in middle thoracic esophagus after surgery.Conclusion The expression levels of MT-3 gene are decreased in middle thoracic esophageal carcinoma,which is correlated with tumor differentiation degree, T staging and lymph node metastasis.The 3-year survival rate in patients with positive expression of MT-3 gene is significantly higher than that of patients with negative expression of MT-3 gene.Therefor MT-3 gene may be used as a molecular marker for evaluating the postoperative prognosis of patients with esophageal squamous cell carcinoma.